InterVenn Stock

InterVenn Biosciences identifies, quantifies, and classifies Glycoproteomic and other PTM signals found in human blood and tissue.

Sign up today and learn more about InterVenn Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About InterVenn Stock

InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides. It was founded in 2017 and headquartered in Redwood City, California.


Funding History

December 2018$9.4M
July 2020$33.7M
November 2020$34.0M
August 2021$201M


Scientific Co-Founder

Carolyn Bertozzi

Co-Founder and CEO

Aldo Carrascoso

Scientific Co-Founder

Carlito Lebrilla

SVP of QA, RA and Customer Excellence

Katherine Dalao

General Manager - Malaysia / VP Business Development

Fadzhairi Jabar

Chief Financial Officer

Brian Hogan


Erwin Estigarribia

Country Manager

Axel Kornerup

Board of Directors

Adam D'Augelli


Sunil Dhaliwal

Board of Directors

Jenny Rooke


Ryan Bethencourt

Senior Director of Pre-clinical R&D

Xin Cong

InterVenn Distinguished Scientist

Klaus Lindpaintner

Board Member

David Michael

Chief Medical Officer

Tillman Pearce


Kenan Pandza


John Leite

Chief Data Officer

Dan Serie

VP, Clinical Development

Kaitlynn Moser


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: